Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company leverages its novel cell penetrating peptide technology platform to create therapies. Its lead product candidate is CTI-1601, which is currently in a Phase 2 open-label extension (OLE) clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disorder. The company is dedicated to addressing unmet medical needs in rare disease areas, with a primary focus on advancing CTI-1601 through clinical development.

Larimar Therapeutics, Inc. is listed on the NasdaqGM exchange under the ticker symbol LRMR. The company's shares are traded in US Dollars (USD). As a US-based company, it is part of the Nasdaq Global Market, which is a tier of the Nasdaq stock exchange that lists companies meeting certain financial and liquidity requirements. Investors can buy and sell LRMR shares during regular trading hours on Nasdaq.

Larimar Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and technologies to develop drugs and therapies. The company's work is centered on rare diseases, which falls under the broader biotech umbrella. Biotechnology companies like Larimar often engage in research and development, clinical trials, and regulatory processes to bring new treatments to market.

Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania, United States. This location serves as the company's corporate headquarters. Bala Cynwyd is a suburb of Philadelphia, placing the company in a region with a strong life sciences presence. The company primarily serves the US market, as its clinical trials and regulatory activities are focused within the United States. Being headquartered in the US allows Larimar to closely collaborate with research institutions and regulatory bodies like the FDA.